MedX Expects Accelerated Revenue Growth From World's Largest Economy
MISSISSAUGA, ON, March 4 /PRNewswire-FirstCall/ - MedX Health Corp., (TSXV.MDX) a global leader in developing drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced that the company has received CE Mark approval to market and sell the family of MedX laser and light products in all 25 European Union (EU) and three European Free Trade Association Member (EFTA) states. The CE Mark certifies that the MedX laser and light products have met EU health, safety and environmental requirements that ensure consumer and workplace safety.
"The CE Mark approval allows MedX to establish its global presence beyond North America, and further validates the benefits delivered through our non-invasive, drug-free products," states Steve Guillen, president and CEO of MedX Health. "This announcement comes shortly after achieving the International Organization of Standardization (ISO) re-certification, demonstrating to outside regulatory bodies that the highest quality standards are in place at MedX."
MedX continues to build upon its 10+ years of success in North America of bringing symptom relief in a non-pharmacologic manner to the rehabilitation/chiropractic/sports medicine markets. Through a rapidly growing international distributor network, which now includes the European Union, one of the largest and fastest growing markets in the world, MedX intends to expand its global reach and increase its revenue stream. Strong patent protection as well as developing and commercializing advanced products in the dental and wound care markets will also help position the company to increase revenues around the world. MedX presently holds key patents on its technology, and has received FDA clearance, Health Canada, and now the CE Mark on the family of laser and light products.
About MedX
MedX Health is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technology for use in numerous medical settings that provide patients with non-invasive, drug-free solutions for improving clinical outcomes. MedX's innovative Laser/Light Therapy devices enhance the patient's quality of life and improve the standard of care for tissue repair and pain relief.
MedX is expanding its distribution network and marketing programs globally through strategic partnerships, while continuing to develop and acquire new dental, rehabilitation and wound care products. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market. Recently, MedX announced a new patent allowance for bone growth that will join several key existing patents, including "Photobandage" a new technology that allows a wound to be bathed in light and is designed to enhance the healing process. The Company intends to license its proprietary wound care technologies to one or more major wound care companies for further development, marketing and commercialization.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
CONTACT: Investors: Steve Guillen, President and Chief Executive Officer,
MedX Health Corp., Phone: (905) 826-0766, info@medxhealth.com; Media: Terri
Clevenger, Continuum Health Communications, Phone (203) 227-0209, Email:
tclevenger@continuumhealthcom.com
